Abstract
1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have